The FDA announced on June 4, 2018, that Hospira Inc. of Lake Forest voluntarily recalled Naloxone Hydrochloride Injection USP due to the presence of particulate matter. The recall affects 164,860 syringes distributed nationwide in the U.S., Puerto Rico, and Guam.
How to tell if you have it
- Brand: Hospira
- Product: Naloxone Hydrochloride Injection, USP, 0.4 mg/mL, 1 mL in 2.5 mL Carpuject Single-use cartridge syringe, Single unit
- NDC: 0409-1782-03 (Lot 72680LL, Exp. 1DEC2018)
- NDC: 0409-1782-69 (Lot 76510LL, Exp. 1APR2019)
The hazard
According to the FDA, the hazard is the presence of particulate matter and potential for particulate matter on the syringe plunger.
Context
GovInfoNow's records show Hospira Inc. has one other recall on record since July 26, 2017. Other recent recalls of similar products include GE Healthcare Omnipaque Injection Recall (March 24, 2026), American Regent Tralement injection recall (July 24, 2026), and American Regent Papaverine HCl Injection Recall (July 24, 2026).